The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic

Ann Neurol. 1992 Dec;32(6):795-8. doi: 10.1002/ana.410320614.

Abstract

We undertook an analysis of the hazard functions derived from results published by the Parkinson Study Group following their investigation of deprenyl. Our findings indicate that the action of deprenyl is transient rather than sustained. We also infer that this effect may be mediated through alleviation of symptoms rather than by neuroprotection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Models, Statistical
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Selegiline / therapeutic use*
  • Survival Analysis

Substances

  • Selegiline